Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors

被引:5
|
作者
van de Ven, Steffi E. M. [1 ]
Derikx, Lauranne A. A. P. [2 ]
Nagtegaal, Iris D. [3 ]
van Herpen, Carla M. [4 ]
Takes, Robert P. [5 ]
Melchers, Willem J. G. [6 ]
Pierik, Marieke [7 ]
van den Heuvel, Tim [7 ]
Verhoeven, Rob H. A. [8 ]
Hoentjen, Frank [2 ]
Nissen, L. H. C. [9 ]
机构
[1] Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Otolaryngol & Head & Neck Surg, Nijmegen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[7] Maastricht Univ, Med Ctr, Dept Gastroenterol & Hepatol, Maastricht, Netherlands
[8] Netherlands Comprehens Canc Org, Dept Res & Dev, Utrecht, Netherlands
[9] Jeroen Bosch Hosp, Dept Gastroenterol & Hepatol, Henri Dunantstr 1,Postbox 90153, NL-5200 ME Shertogenbosch, Netherlands
关键词
inflammatory bowel diseases; head and neck cancer; laryngeal carcinoma; immunosuppressive therapy; SQUAMOUS-CELL CARCINOMA; LIVER-TRANSPLANTATION; COLORECTAL-CANCER; CROHNS-DISEASE; ULCERATIVE-COLITIS; NECK-CANCER; NATIONWIDE; NEOPLASIA; HEAD; MALIGNANCY;
D O I
10.1093/ibd/izz210
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Inflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients is increased. The relation between IBD patients and laryngeal cancer (LC) remains unclear. We aimed (1) to identify risk factors in IBD patients for LC development and (2) to compare clinical characteristics, outcome, and survival of LC in IBD patients with the general population. Methods: All IBD patients with LC (1993-2011) were retrospectively identified using the Dutch Pathology Database. We performed 2 casecontrol studies: (1) to identify risk factors, we compared patients with IBD and LC (cases) with the general IBD population; (2) to analyze LC survival, we compared cases with controls from the general LC population. Results: We included 55 cases, 1800 IBD controls, and 2018 LC controls. Cases were more frequently male compared with IBD controls (P < 0.001). For ulcerative colitis (UC), cases were older at IBD diagnosis (P < 0.001). Crohn's disease (CD) cases were more frequently tobacco users (P < 0.001) and more often had stricturing (P = 0.006) and penetrating (P = 0.008) disease. We found no survival difference. Immunosuppressive medication had no impact on survival. Conclusions: Male sex was a risk factor for LC in IBD patients. Older age at IBD diagnosis was a risk factor for UC to develop LC. Tobacco use and stricturing and penetrating disease were risk factors for LC development in CD patients. Inflammatory bowel disease was not associated with impaired survival of LC. Immunosuppressive medication had no influence on survival.
引用
收藏
页码:1060 / 1067
页数:8
相关论文
共 50 条
  • [31] COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE
    Spiera, Emily
    Ganjian, Danielle
    Zhang, Xian
    Brenner, Erica
    Agrawal, Manasi
    Colombel, Jean-Frederic
    Kappelman, Michael
    Kornbluth, Asher
    Ungaro, Ryan
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S104 - S105
  • [32] COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE
    Spiera, Emily
    Ganjian, Danielle
    Zhang, Xian
    Brenner, Erica
    Agrawal, Manasi
    Colombel, Jean-Frederic
    Kappelman, Michael
    Kornbluth, Asher
    Ungaro, Ryan
    GASTROENTEROLOGY, 2022, 162 (03) : S104 - S105
  • [33] Factors Associated With Readmissions and Outcomes of Patients Hospitalized for Inflammatory Bowel Disease
    Nguyen, Geoffrey C.
    Bollegala, Natasha
    Chongk, Christopher A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (11) : 1897 - U381
  • [34] RISK FACTORS AND TREATMENT OUTCOMES OF PERISTOMAL PYODERMA GANGRENOSUM IN INFLAMMATORY BOWEL DISEASE
    Wang, Jingzhou D.
    Prenner, Joshua C.
    Wang, Wenfei
    Sakuraba, Atsushi
    Hyman, Neil
    Dalal, Sushila
    Hurst, Roger D.
    Cohen, Russell D.
    Umanskiy, Konstantin
    Shogan, Benjamin D.
    Alpert, Lindsay
    Rubin, David T.
    Colwell, Janice
    Pekow, Joel R.
    GASTROENTEROLOGY, 2020, 158 (06) : S931 - S931
  • [35] Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease
    Yamamoto-Furusho, Jesus K.
    Fonseca-Camarillo, Gabriela
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (11) : 2683 - 2695
  • [36] Clinical Features and Outcomes in Patients with Inflammatory Bowel Disease and Concomitant Sarcoidosis
    Shahi, Varun
    Khanna, Sahil
    Loftus, Edward
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S557 - S557
  • [37] The Impact of Thiopurine Hypermethylation on Clinical Outcomes in Patients With Inflammatory Bowel Disease
    Blaker, Paul A.
    Fong, Steven C.
    Smith, Melissa A.
    Kariyawasam, Viraj C.
    Marinaki, Anthony M.
    Irving, Peter M.
    Sanderson, Jeremy D.
    GASTROENTEROLOGY, 2014, 146 (05) : S246 - S246
  • [38] Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
    Gara, Sirisha K.
    Guntipalli, Prathima
    Marzban, Sima
    Taqi, Muhammad
    Aryal, Vinayak
    Khan, Qurat ul ain
    Shah, Shahtaj A.
    Akbariromani, Hanieh
    Salinger, Darren
    Diaz-Miret, Miguel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [39] Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients
    Ribaldone, Davide Giuseppe
    Vernero, Marta
    Parisi, Simone
    Ditto, Maria Chiara
    Pellicano, Rinaldo
    Morino, Mario
    Saracco, Giorgio Maria
    Fusaro, Enrico
    Astegiano, Marco
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2019, 54 (10) : 1233 - 1236
  • [40] Toxicity of thiopurines in patients with inflammatory bowel disease: Frequency and risk factors
    Ben Mustapha, N.
    Labidi, A.
    Serghini, M.
    Fekih, M.
    Boubaker, J.
    Filali, A.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S194 - S194